Non-radioactive method to measure organ blood flow

描述(逐字摘自申请人的摘要)：在第一阶段测试的假设是稳定的同位素标记微球和中子 激活技术可以用来测量活体模型中的局部器官灌注量。我们成功地验证了我们的假设并演示了概念 可行性。我们第一阶段研究的结果显示，血流数值 从稳定的同位素标记的微球中获得的结果与 从放射性微球中获得。第11阶段将开发新产品和 支持我们的微球产品线并推进其商业化的系统， 潜力。第11阶段将开发使用浓缩同位素的新微球标记 以最大限度地提高化验的灵敏度，并最大限度地减少 元素的活化产物。我们还将把这项工作扩展到标签 用于其他灌流研究领域的额外大小的微球。 我们将表征标记浓度并评估微球标记 在一系列条件下的稳定性。此外，第二阶段将制定一个 新型自动康普顿抑制，符合计数系统，将 提高络合物光谱分析的灵敏度和特异性 中子活化后的伽马射线能谱。最后，我们将设计和 描述一种能够大量激活中子的自动样品输送系统 样本数。建设将是由BioPAL资助的第三阶段项目。 建议的商业应用： 基于中子活化的分析方法可以在体内系统内同时跟踪多个稳定同位素标记的研究产品。这种能力引起了生物医学研究界的高度兴趣。目前还没有哪种技术可以提供这种程度的多功能性。

DESCRIPTION (Verbatim from the Applicant's Abstract): The hypothesis tested during Phase I was that stable isotope-labeled microspheres and neutron activation technology can be used to measure regional organ perfusion within in vivo models. We successfully proved our hypothesis and demonstrated concept feasibility. The results of our Phase I study show that blood flow values obtained from stable isotope-labeled microspheres compare favorably to values obtained from radioactive microspheres. Phase 11 will develop new products and systems to support our microsphere product-line and advance its commercial, potential. Phase 11 will develop new microsphere labels using enriched isotopes to maximize the sensitivity of the assay and to minimize the production of activation products of the element. We will also extend this work to label additional sizes of microspheres for uses in other areas of perfusion research. We will characterize label concentration and evaluate microsphere label stability over a range of conditions. In addition, Phase II will develop a novel automated Compton-suppression, coincidence-counting system that will improve the sensitivity and specificity of spectrographic analysis of complex gamma-ray spectra following neutron activation. Finally, we will design and characterize an automated sample delivery system to neutron activate large numbers of samples. Construction will be a Phase III project funded by BioPAL. PROPOSED COMMERCIAL APPLICATION: Neutron activation-based assays can simultaneously track multiple stable-isotope labeled research products within in vivo system. This ability is of high interest to the biomedical research community. No current technology can provide this level of versatility.